Home » Stocks » PROG

Progenity, Inc. (PROG)

Stock Price: $5.47 USD -0.10 (-1.80%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $5.40 -0.07 (-1.28%) Feb 26, 7:28 PM
Market Cap 298.91M
Revenue (ttm) 80.51M
Net Income (ttm) -167.48M
Shares Out 46.63M
EPS (ttm) -3.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $5.47
Previous Close $5.57
Change ($) -0.10
Change (%) -1.80%
Day's Open 5.41
Day's Range 5.40 - 5.61
Day's Volume 319,879
52-Week Range 3.08 - 15.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...

Newsfile Corp - 5 days ago

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. (NASDAQ: PROG) ("Silk Road" or the "Company"). Such i...

PRNewsWire - 1 week ago

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advise...

GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testin...

GlobeNewsWire - 2 weeks ago

Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of t...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such i...

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

Benzinga - 2 weeks ago

Progenity's (NASDAQ:PROG) stock has been falling Monday, down 6.19% to a price of $5.9. Monday the stock has been traded at a volume of 209.31 thousand, about 29.44% of its recent 30-day volum...

GlobeNewsWire - 1 month ago

The company celebrates its ten-year anniversary and looks toward future innovations The company celebrates its ten-year anniversary and looks toward future innovations

GlobeNewsWire - 1 month ago

Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

24/7 Wall Street - 2 months ago

Initial public offerings (IPOs) have been a hot topic of late, with big names like Airbnb and DoorDash having some of the biggest showings this year.

Other stocks mentioned: ANPC, CSPR, DNK, GRIL, LIZI, VEL
GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

Benzinga - 2 months ago

Adam Johnson of BullseyeBrief.com presented Tuesday at the Benzinga Global Small Cap Conference, discussing his fund of small-cap stock picks on Bullseye Brief, where subscribers can track his...

Other stocks mentioned: KOP, REAL
GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior ...

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amou...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...

GlobeNewsWire - 3 months ago

High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

Seeking Alpha - 3 months ago

Progenity, Inc. (PROG) CEO Harry Stylli on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

GlobeNewsWire - 3 months ago

Announces Expansion of its COVID-19 Testing Offering

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 27, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and...

GlobeNewsWire - 4 months ago

Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 26, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Progenity, Inc. ("Progenity" ...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 26, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 26, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $PROG #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 27, 2020 deadline to file a lead plaintiff motion in the class a...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Progenity, Inc. ("Progenity" or "the Company") (NASDAQ: PROG...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 23, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 22, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and...

Newsfile Corp - 4 months ago

[DATELINE] The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progenity, Inc. (NASDAQ: PROG) ("Progenity" or "the Compan...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 19, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Prog...

PRNewsWire - 4 months ago

NEW YORK, Oct. 17, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Progenity" or the "Company") (NASDAQ: PROG). Such investors are advise...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 15, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant an...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/or traceable to the Company’s ...

GlobeNewsWire - 4 months ago

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 7, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Proge...

PRNewsWire - 4 months ago

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/or traceable to th...

PRNewsWire - 4 months ago

NEW YORK and SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed agai...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 5, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Progen...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 2, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/...

About PROG

Progenity, a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was former... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2020
CEO
Harry Stylli
Employees
702
Stock Exchange
NASDAQ
Ticker Symbol
PROG
Full Company Profile

Financial Performance

In 2019, Progenity's revenue was $143.99 million, an increase of 12.51% compared to the previous year's $127.97 million. Losses were -$148.04 million, 14.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Progenity stock is "Strong Buy." The 12-month stock price forecast is 9.40, which is an increase of 71.85% from the latest price.

Price Target
$9.40
(71.85% upside)
Analyst Consensus: Strong Buy